Belgium-based iTeos debuts to focus on cancer immunotherapy

Cancer immunotherapy company iTeos Therapeutics S.A. (Gosselies, Belgium) debuted on Thursday with a EUR 3 million ($4 million) series A round from Ludwig Institute for Cancer Research (LICR); Hunza Ventures; Life Science Research Partners; Vives Louvain Technology Fund; and angel investors. iTeos is developing preclinical small molecule immunomodulators that it hopes to combine with existing cancer vaccines initially in pancreatic, lung and colorectal cancers. ...